Summary of project PR000313

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench,, where it has been assigned Project ID PR000313. The data can be accessed directly via it's Project DOI: 10.21228/M8QG7W This work is supported by NIH grant, U2C- DK119886.


Project ID: PR000313
Project DOI:doi: 10.21228/M8QG7W
Project Title:Inhibition of diamine oxidase promotes uptake of putrescine from rat small intestine
Project Summary:Metformin, a biguanide molecule, which is used as first line therapy for type 2 diabetes. In this study, we would like to investigate the inhibition of an enzyme called diamine oxidase (DAO) (also known as ABP1), by metformin. Based on our preliminary in vitro study using diamine oxidase enzyme, we saw increased level of putrescine with increasing metformin concentrations (see reference PMID: 26335661). This proposed in vivo study was to determine whether metformin could increase putrescine levels and other metabolites in mice. Aminoguanidine, a known inhibitor of DAO, in this study as positive control, following similar study design described in this paper (PMID: 8912017).
Institute:University of California, Davis
Department:Genome and Biomedical Sciences Facility
Laboratory:WCMC Metabolomics Core
Last Name:Fiehn
First Name:Oliver
Address:1315 Genome and Biomedical Sciences Facility, 451 Health Sciences Drive, Davis, CA 95616
Phone:(530) 754-8258
Funding Source:NIH U24DK097154

Summary of all studies in project PR000313

Study IDStudy TitleSpeciesInstituteAnalysis
(* : Contains Untargted data)
(* : Contains raw data)
ST000401 Inhibition of diamine oxidase promotes uptake of putrescine from rat small intestine Rattus norvegicus University of California, Davis MS 2016-06-18 1 40 Uploaded data (310.7M)*